SBRT治疗I-II期NSCLC患者心脏亚结构剂量与非癌死亡相关
本研究纳入803例接受SBRT的早期NSCLC患者,主要方案为3×18Gy(59%)或4×12Gy(19%)。中位随访34.8个月,2年总生存率67%,死亡患者中26.8%死于癌症。多变量分析显示左心房最大剂量(中位6.5Gy EQD2,HR=1.005,p=0.035)和上腔静脉90%体积剂量(中位0.59Gy EQD2,HR=1.025,p=0.008)与非癌死亡显著相关,敏感性分析识别心脏上部区域(心房+血管)与非癌死亡显著相关。
要点
- 左心房最大剂量和上腔静脉D90与非癌死亡显著相关。
- 心脏上部区域(心房+血管)剂量与非癌死亡显著相关。
- 心脏上部区域剂量保护可能改善预后,需进一步研究。
核心结论
- 主要心脏上部区域的剂量与非癌死亡显著相关,保护该区域剂量可能改善预后。
研究设计与样本
- 研究纳入803例接受SBRT的早期NSCLC患者,主要方案为3×18Gy(59%)或4×12Gy(19%),所有患者配准至平均解剖并变形计划剂量以获得心脏亚结构剂量学参数。
- 采用多变量Cox回归和敏感性分析识别与非癌死亡显著相关的心脏亚结构或心脏区域剂量。
主要发现
- 中位随访34.8个月,2年Kaplan-Meier总生存率为67%。
- 死亡患者中26.8%死于癌症。
- 多变量分析显示左心房最大剂量(中位6.5Gy EQD2,范围0.009-197,HR=1.005,p=0.035)与非癌死亡显著相关。
- 多变量分析显示上腔静脉90%体积剂量(中位0.59Gy EQD2,范围0.003-70,HR=1.025,p=0.008)与非癌死亡显著相关。
- 敏感性分析识别心脏上部区域(心房+血管)与非癌死亡显著相关。
临床怎么用
- 在SBRT计划设计时,可考虑对心脏上部区域(尤其左心房和上腔静脉)进行剂量保护,以潜在降低非癌死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To investigate potential associations between dose to heart (sub)structures and non-cancer death, in early stage non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT). METHODS: 803 patients with early stage NSCLC received SBRT with predominant schedules of 3×18Gy (59%) or 4×12Gy (19%). All patients were registered to an average anatomy, their planned dose deformed accordingly, and dosimetric parameters for heart substructures were obtained. Multivariate Cox regression and a sensitivity analysis were used to identify doses to heart substructures or heart region with a significant association with non-cancer death respectively. RESULTS: Median follow-up was 34.8months. Two year Kaplan-Meier overall survival rate was 67%. Of the deceased patients, 26.8% died of cancer. Multivariate analysis showed that the maximum dose on the left atrium (median 6.5Gy EQD2, range=0.009-197, HR=1.005, p-value=0.035), and the dose to 90% of the superior vena cava (median 0.59Gy EQD2, range=0.003-70, HR=1.025, p-value=0.008) were significantly associated with non-cancer death. Sensitivity analysis identified the upper region of the heart (atria+vessels) to be significantly associated with non-cancer death. CONCLUSIONS: Doses to mainly the upper region of the heart were significantly associated with non-cancer death. Consequently, dose sparing in particular of the upper region of the heart could potentially improve outcome, and should be further studied.
引用
- Stam B, Peulen H, Guckenberger M, et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. Radiother Oncol. 2017. PMID: 28476219. doi:10.1016/j.radonc.2017.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。